Resumo

ROBLEDO, Melissa et al. SLCO1B1 gene utility as a marker of interest in the pharmacogenomics of statins. Rev. Colomb. Cardiol. [online]. 2019, vol.26, n.1, pp.24-30. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2018.05.006.

Cardiovascular diseases are the main cause of death in the world. Lipid-lowering drugs like statins are the first alternative in the primary prevention of cardiovascular events, strokes, and revascularisation procedures. These drugs are HMG-CoA reductase inhibitors, which regulate the rate of cholesterol synthesis, as well as increase its liver uptake via the LDL receptor pathway. The organic anion transporter polypeptide 1B1 (OATP1B1) coded by the solute carrier organic anion transporter 1B1 (SLCO1B1) gene is one of the hepatic influx and efflux transporters of statins. In genome-wide association studies (GWAS) different single nucleotide polymorphisms (SNPs) have been reported within the SLCO1B1 gene that are able to reduce the statin uptake mediated by OATP1B1. This suggests that the variations in the sequencing of this gene have an influence on the pharmacokinetics and pharmacodynamics of these drugs, leading to a condition known as statin-induced myopathy. Genes that affect cardiovascular treatments, as well as the current advances in diagnostic tests based on their sequencing, now offer the possibility of revolutionising their diagnosis and treatment. They could be used with the aim of validating risk prediction, prognosis, prevention, and management of patients with a risk of cardiovascular diseases, and will lead to the development of new forms of medical treatments.

Palavras-chave : Cardiovascular disease; Statin; Gene; Pharmacogenomic variants.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )